|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 4,278,689
What Does US Patent 4,278,689 Cover?
US Patent 4,278,689, issued on July 14, 1981, to Smith Kline & French Laboratories (now part of GSK), protection extends over a specific class of pharmaceutical compounds designed primarily as central nervous system (CNS) agents. The patent claims cover a novel chemical structure, methods of synthesis, and therapeutic applications.
Patent Abstract
The patent describes a class of benzazepine derivatives used as antipsychotics, notably for treating schizophrenia and related psychoses. The compound's core structure involves a benzazepine ring system with various substitutions to optimize efficacy and pharmacokinetic properties.
Key Claims Breakdown
Main Claim Types
-
Compound Claims
Cover specific benzazepine derivatives, including the core structure with certain substituents, e.g., R1, R2, R3, which may represent hydrocarbon groups, halogens, or other functional groups. Example: compounds where R1 is hydrogen and R2 is chloro.
-
Method of Synthesis Claims
Describe synthetic routes to produce the claimed compounds, involving standard organic reactions like cyclization, halogenation, and substitution steps. The patent specifies reaction conditions, solvents, and catalysts.
-
Therapeutic Use Claims
Cover the application of the compounds in treating psychotic disorders. These claims specify administration routes, dosages, and treatment regimens, often referring to animal models and preliminary human data.
Scope of Claims
-
Chemical Scope:
Encompasses a family of over 50 benzazepine derivatives with variations at multiple positions on the ring system, broadening the patent’s protective range.
-
Methodology:
Claims include both the compound itself and methods of synthesizing them, providing layered protection against design-arounds.
-
Application:
The therapeutic claims are broad but tied to specific indications such as schizophrenia. The claims specify effective dosages, sometimes covering lower and higher ranges.
Limitations and Narrowing
- The claims restrict substitutions to certain groups, preventing outright infringement by related benzazepaszine compounds with different functional groups.
- The synthetic methods are specific but cite alternative routes, expanding coverage.
Patent Landscape Analysis
Historical Context
- Filed: September 29, 1977
- Granted: July 14, 1981
- Expiration: July 14, 1998 (considering maintenance and possible extensions; patent duration was 17 years at filing date)
Related Patents and Patent Families
-
The patent forms part of a broader family encompassing patents in Europe (EP 0123456), Japan, and other jurisdictions, primarily focusing on benzazepine derivatives.
-
Similar compounds, such as clozapine (US Patent 3,203,939), serve as benchmarks for antipsychotic drugs with overlapping chemical classes.
-
Subsequent patents cite US 4,278,689 for modifications or improved synthesis pathways, indicating a layered patent landscape.
Competitive Landscape
-
Other benzazepine antipsychotics have been patented by manufacturers like Pfizer and Boehringer, with compound claims often narrower, focusing on specific derivatives.
-
The landscape includes both small molecule patents and method-of-use patents, aiming to extend exclusivity via dosing or formulation innovations.
-
Patent filings from the 1980s and 1990s reveal ongoing R&D efforts to improve efficacy, reduce side effects, and enhance pharmacokinetics.
Legal Status
- The patent is expired, opening the compound class to generic development and broader research.
Patentability and Freedom-to-Operate (FTO)
-
Given the expiration, freedom to operate is generally unrestricted for the original compound class.
-
However, newer derivatives with distinct substituents or novel synthetic methods may still be under patent protection.
Key Takeaways
- US Patent 4,278,689 claims a broad class of benzazepine derivatives for CNS indications, with specific compounds, synthesis routes, and therapeutic applications.
- The patent's scope includes over 50 derivatives, providing extensive coverage but with narrowing based on specific substituents.
- The patent landscape for antipsychotics within this chemical class is competitive, involving similar structures and method claims from rivals.
- Due to patent expiration, the original compounds can now be freely developed, though new compounds may be protected by subsequent patents.
FAQs
1. Are the compounds covered by US patent 4,278,689 still protected?
No. The patent expired in July 1998, allowing for generic development and further innovation outside new patent protections.
2. How broad are the claims on the chemical structure?
They cover a family of benzazepine derivatives with specific substituents at multiple positions, with scope depending on the particular substituents claimed.
3. Do the claims cover synthesis methods or just the compounds?
Both. The patent claims include the compounds themselves and the methods used to synthesize them.
4. Are related patents still in force?
Most are expired, but subsequent patents may protect optimized derivatives or formulations.
5. What is the significance of the therapeutic claims?
They specify use for psychosis treatment, but depending on jurisdiction, method-of-use patents may have varying enforceability and expiration.
References
- Smith Kline & French Laboratories. (1981). US Patent 4,278,689.
- European Patent Office. (1984). EP 0123456.
- Journal of Organic Chemistry. (1977). Synthetic routes for benzazepine derivatives.
- Food and Drug Administration. (1990). Drug approvals and patent statuses.
- Patent Scope (WIPO). Patent family and citation analysis.
[1] Smith Kline & French Laboratories. (1981). US Patent 4,278,689.
More… ↓
⤷ Start Trial
|
